<DOC>
	<DOCNO>NCT00535028</DOCNO>
	<brief_summary>This single center , double-blind , randomise parallel group design study investigate effect AER 001 late phase asthmatic resonse asthmatic subject . AER 001 administer subcutaneously ( 25 mg , daily ) 28 day . The asthmatic subject challenge allergen AER 001 treatment ( screen Day 28 ) . The primary outcome late phase sthmatic response ( max drop FEV1 4-10 hour allergen challenge ) .</brief_summary>
	<brief_title>A Phase IIa Study Subcutaneous AER 001 Antigen Challenge In Atopic Asthmatic Subjects ( 28 Day Study )</brief_title>
	<detailed_description>Objectives : Primary Objective - To investigate late asthmatic response mild moderate asthmatics.. Secondary Objectives - To examine effect AER 001 cutaneous antigen response , antigen induce airway hyperactivity sputum eosinophilia . Methodology : Study Design : - Single centre , phase IIa , double-blind , randomise , parallel group , repeat dose study male female asthmatic subject . - A sufficient number subject ( least 24 subject ) recruit ensure least 20 complete set data obtain . - Subjects randomise receive either AER 001 25 mg / Placebo ratio 1 active : 1 placebo . - Treatments administer sub-cutaneous injection . - Subjects receive daily administration AER 001 / placebo 4 week period . - Subjects admitted unit least 2 hour prior first dose administration . On first dose occasion subject remain unit clinical supervision least 30 minute post dose Investigator satisfy discharge . On subsequent dosing day subject admitted unit least 45 minute prior dose remain unit least 15 minute post dose Investigator satisfy discharge .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>• Adult male female &gt; 18 year . Subjects female , currently pregnant breast feed use medically acceptable method contraception . Subjects pre study medical history , physical examination , 12 Lead ECG acceptable investigator . Subjects clinical laboratory test within reference range clinically acceptable investigator . Subjects negative HbsAg , hepatitis C antibody HIV II I test screen . Subjects negative drug abuse alcohol test screen admission . Positive response screen skin prick test . Subjects respond &lt; 8 mg / mL methacholine challenge . Subjects , Allergen challenge , PC20 allergen exhibit late phase response ( &gt; = 15 % 410h ) follow allergen challenge . Subjects FEV1 &gt; 70 % predict . Have receive steroid treatment prior month . Subjects nonsmoker least 3 month prior screen . Have &lt; 10 pack year history . Satisfies Global Initiative Asthma ( GINA , 2002 ) definition asthma treatment asthma . Subjects stable , adequately treat medical condition may enrol provide Principal Investigator consider study participation place increase risk adverse event . Subjects continue concomitant treatment without change study . Subjects able willing give write informed consent . • Subjects conform inclusion criterion . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . Which would preclude antigen challenge Subjects clinically relevant surgical history . Which would preclude antigen challenge Subjects clinically relevant family history . Which would preclude antigen challenge Subjects history relevant drug hypersensitivity . Subjects history alcoholism . Subjects history drug abuse . Subjects consume 28 unit alcohol week . ( unit = 1 glass wine = 1 measure spirit = ½ pint beer ) Subjects significant infection know inflammatory process screening . Subjects acute gastrointestinal symptom time screen and/or admission ( e.g . nausea , vomit , diarrhoea , heartburn ) Subjects acute infection influenza time screen and/or admission . Female subject use acceptable method contraception . Subjects use investigational drug /or participate clinical trial within 3 month first dose . Subjects use medication , opinion Investigator affect outcome study . Subjects donate and/or receive blood blood product within previous 3 month prior first dose ( review case case basis ) . Subjects communicate reliably investigator . Subjects unlikely cooperate requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>asthma</keyword>
	<keyword>allergy</keyword>
	<keyword>interleukin-4</keyword>
	<keyword>interleukin-13</keyword>
	<keyword>IL-4</keyword>
	<keyword>IL-13</keyword>
	<keyword>atopic</keyword>
	<keyword>late asthmatic response</keyword>
	<keyword>inflammation</keyword>
</DOC>